Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Patients With PBC
-
- STATUS
- Recruiting
-
- End date
- Dec 14, 2023
-
- participants needed
- 60
-
- sponsor
- Intercept Pharmaceuticals
Summary
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC).
Details
| Condition | Primary Biliary Cholangitis |
|---|---|
| Treatment | Obeticholic acid placebo, Bezafibrate 200 MG, Bezafibrate 100 MG, Obeticholic Acid 5 MG, Bezafibrate Placebo |
| Clinical Study Identifier | NCT05239468 |
| Sponsor | Intercept Pharmaceuticals |
| Last Modified on | 7 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer